Makena’s Reimbursement Coverage Remained Unchanged After Confirmatory Trial Failure

As milestone approaches in FDA effort to pull the pre-term birth drug, the findings suggest that by leaving Makena on the market, the agency may be ‘furthering plan inaction,’ Tufts Medical Center researchers conclude.